Important note: Information in this article was accurate in 2002. The state of the art may have changed since the publication date.
|
|
AIDS Weekly (12.16.02) - Wednesday, December 18, 2002
Michael Greer
Mycobacterial drug resistance had little effect on the outcome of treatment for infected adults studied by G.W. Thwaites and colleagues at the University of Oxford-Wellcome Trust Clinical Research Unit in Ho Chi Minh City and other institutions in Vietnam, Thailand, and the United Kingdom. The researchers examined 56 Vietnamese tuberculous meningitis patients, confirmed by cerebrospinal fluid culture. Patients coinfected with HIV were significantly more likely to carry mycobacterial populations resistant to streptomycin and isoniazid, according to the study.
However, data showed that neither isoniazid nor streptomycin resistance was associated with increased mortality risks. Microbial genotype and HIV coinfection also failed to impact patient mortality rates. The only clinical variable linked to heightened mortality risk was coma score. This variable independently predicted death during hospitalization.
"Treatment of tuberculous meningitis before the onset of coma saves lives," Thwaites and others wrote. "Resistance to isoniazid and/or streptomycin does not appear to affect outcome." Their full report, "Isoniazid Resistance, Mycobacterial Genotype and Outcome in Vietnamese Adults with Tuberculous Meningitis," was published in the International Journal of Tuberculosis and Lung Disease (2002;6(10):865-871).
021218
AD022447
Copyright © 2002 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
.